Primary HIV-1 infection: to treat or not to treat?
Treatment of primary HIV-1 infection with HAART may represent a unique opportunity to alter the course of this chronic disease. In spite of this, enthusiasm for the "ht early, hit hard" approach has waned over time, given the lack of data showing long-term clinical benefit. This article will examine the risks and benefits of starting HAART during acute HIV-1 disease.
Blankson
Joel N
JN
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
D000208:Acute Disease; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D003657:Decision Making; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans
D019380:Anti-HIV Agents